scholarly journals Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer

Cancer ◽  
2009 ◽  
Vol 115 (9) ◽  
pp. 1924-1931 ◽  
Author(s):  
Antonio Russo ◽  
Sergio Rizzo ◽  
Fabio Fulfaro ◽  
Vincenzo Adamo ◽  
Daniele Santini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Cell Lung Cancer ◽  
Single Agent ◽  
Nonsmall Cell Lung Cancer ◽  
Single Agent Therapy

scholarly journals Second-line combination therapies in nonsmall cell lung cancer without known driver mutations

2015 ◽  
Vol 24 (138) ◽  
pp. 582-593 ◽  
Author(s):  
Maria-Virginia Bluthgen ◽  
Benjamin Besse
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Single Agent ◽  
Nonsmall Cell Lung Cancer ◽  
Driver Mutation ◽  
Cytotoxic Agents ◽  
Second Line ◽  
Single Agent Therapy ◽  
Platinum Salts ◽  
Nsclc Patients

In advanced nonsmall cell lung cancer (NSCLC) patients, platinum-based combination chemotherapy is standard treatment in the first-line setting; however, the large majority of patients ultimately progress. For more than a decade, single-agent therapy with docetaxel, pemetrexed or erlotinib has been the standard of care after failure with platinum salts, showing some benefit over best supportive care. Nonetheless, prognosis remains poor and new second-line strategies are urgently needed. Combinations of cytotoxic agents, including rechallenge with platinum salts, do not offer clear benefit over single-agent therapy for the majority of patients. In patients without a known tumoural oncogenic driver mutation, regimens based on combinations of targeted agents have shown promising results; however, a clear role in therapeutic management is yet to be established. Some success has been reported in recent research combining a cytotoxic agent with targeted therapies.In this review, we summarise published data for the various strategies evaluated over the past decade in second-line treatment of NSCLC patients without a known driver mutation. We focus on combination treatments and consider future perspectives, including the need to identify predictive markers to support personalised therapeutic strategies.

Adjuvant Chemotherapy in Elderly Patients with NonSmall-Cell Lung Cancer

2007 ◽  
Vol 14 (1) ◽  
pp. 57-62 ◽  
Author(s):  
Cesare Gridelli ◽  
Paolo Maione ◽  
Daniela Comunale ◽  
Antonio Rossi
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Elderly Patients ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer

scholarly journals Racial disparities and survival for nonsmall-cell lung cancer in a large cohort of black and white elderly patients

Cancer ◽  
2009 ◽  
Vol 115 (20) ◽  
pp. 4807-4818 ◽  
Author(s):  
Dale Hardy ◽  
Rui Xia ◽  
Chih-Chin Liu ◽  
Janice N. Cormier ◽  
Zhannat Nurgalieva ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Racial Disparities ◽  
Cell Lung Cancer ◽  
Nonsmall Cell Lung Cancer ◽  
Large Cohort ◽  
Black And White ◽  
White Elderly

A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer

2014 ◽  
Vol 15 (2) ◽  
pp. 96-102 ◽  
Author(s):  
Ikuo Sekine ◽  
Hiroaki Okamoto ◽  
Takeshi Horai ◽  
Kazuhiko Nakagawa ◽  
Hironobu Ohmatsu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Single Agent ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
Phase Iii Study

PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis

2021 ◽  
Author(s):  
Alessandro Di Federico ◽  
Andrea De Giglio ◽  
Giacomo Nuvola ◽  
Chiara Deiana ◽  
Nicole Conci ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Meta Analysis ◽  
Single Agent ◽  
Objective Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Single Agent Therapy

Introduction: The best treatment for advanced, PD-L1-high non-small-cell lung cancer remains a debated issue. Methods: A meta-analysis of randomized clinical trials (RCTs) was performed to compare the efficacy and safety of PD-(L)1 inhibitors alone or plus chemotherapy (CT) for advanced, PD-L1-high non-small-cell lung cancer. Results: 14 RCTs were included. The combination of a PD-(L)1 inhibitor with CT resulted in the improvement of progression-free survival (HR: 0.59; 95% CI: 0.43–0.79; p = 0.0005) and objective response rate (RR: 1.66; 95% CI: 1.14–2.42; p = 0.008). No overall survival difference was documented (HR: 0.99; 95% CI: 0.77–1.27; p = 0.95). The risk of grade ≥3 treatment-related adverse events was significantly reduced with immune-checkpoint inhibitor single-agent therapy compared with immune-checkpoint inhibitors plus CT (RR: 0.38; 95% CI: 0.32–0.45; p = 0.00001). Conclusion: The combination of a PD-(L)1 inhibitor and CT appears to be associated with improved PFS and ORR, but similar OS, compared with PD-(L)1 inhibitor single-agent therapy in patients with PD-L1-high non-small-cell lung cancer.

scholarly journals Nonsmall Cell Lung Cancer Therapy: Insight into Multitargeted Small-Molecule Growth Factor Receptor Inhibitors

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Mridul Roy ◽  
Yu-Hao Luo ◽  
Mao Ye ◽  
Jing Liu
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Single Agent ◽  
Growth Factor Receptor ◽  
Cancer Therapeutics ◽  
Nonsmall Cell Lung Cancer ◽  
Combination Strategies ◽  
Self Sufficiency

To date, lung cancer is the leading cause of cancer-related death worldwide, among which nonsmall cell lung cancer (NSCLC) comprises about 85%. Taking into account the side effects of surgery, radiation, platinum-based doublet chemotherapy, and the growth self-sufficiency characteristic of cancer cells, drugs have been discovered toward growth factor receptor (GFR) to treat NSCLC. As expected, these drugs provide a greater benefit. To increase the efficacy of such growth factor receptor tyrosine kinase inhibitors (RTKIs), coinhibition of GFR signaling pathways and combination of inhibitors along with radiation or chemotherapy have drew intense insight. Although clinical trials about single-agent RTKIs or their combination strategies suggest their increase potency against cancer, they are not beyond adverse effects, and sometimes the effects are more deadly than chemotherapy. Nevertheless the hope for RTKIs may be proved true by further researches and digging deep into cancer therapeutics.

A Phase I Dose Escalation Study of Weekly Docetaxel and Carboplatin in Elderly Patients With Nonsmall Cell Lung Cancer

2007 ◽  
Vol 30 (1) ◽  
pp. 51-56 ◽  
Author(s):  
Kyoichi Kaira ◽  
Satoshi Tsuchiya ◽  
Noriaki Sunaga ◽  
Noriko Yanagitani ◽  
Satoru Watanabe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Phase I ◽  
Cell Lung Cancer ◽  
Dose Escalation ◽  
Nonsmall Cell Lung Cancer ◽  
Dose Escalation Study ◽  
Weekly Docetaxel
Sign in / Sign up

Export Citation Format

Share Document